KRYS Krystal Biotech, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1711279 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY26.0%
TTM net income YoY13.2%
TTM EPS YoY10.3%
Revenue 3-yr CAGR280.1%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin48.4%
Net margin47.9%
FCF margin66.0%
EBITDA margin49.7%
Returns
ROE17.5%
ROA15.9%
ROIC (approx.)23.0%
Asset turnover0.33x
Leverage & solvency
Liabilities / assets9.5%
Debt / equity0.00x
Current ratio7.89x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.44x
Accruals ratio-7.0%
Payout ratio—
Capex / revenue2.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $389.13M | $290.51M |
| R&D expense | $58.05M | $53.58M |
| SG&A expense | $146.74M | $113.63M |
| Operating income | $161.29M | $65.75M |
| Pretax income | $189.47M | $95.36M |
| Income tax | -$15.36M | $6.20M |
| Net income | $204.83M | $89.16M |
| EBITDA | $167.02M | $71.72M |
| EPS (basic) | 7.08 | 3.12 |
| EPS (diluted) | 6.84 | 3.00 |
| Weighted avg. shares (diluted) | 29.95M | 29.74M |
| Balance sheet | ||
| Cash & equivalents | $496.30M | $344.87M |
| Short-term investments | $331.49M | $252.65M |
| Receivables | $127.42M | $104.75M |
| Inventory | $40.48M | $26.51M |
| Current assets | $1.02B | $742.04M |
| PP&E, net | $150.78M | $155.17M |
| Total assets | $1.33B | $1.06B |
| Current liabilities | $102.94M | $102.00M |
| Total liabilities | $114.23M | $109.46M |
| Shareholders' equity | $1.22B | $946.38M |
| Shares outstanding | 29.19M | 28.79M |
| Cash flow statement | ||
| Operating cash flow | $200.87M | $123.42M |
| Capital expenditure | $11.95M | $4.24M |
| Free cash flow | $188.91M | $119.18M |
| Investing cash flow | -$58.42M | -$163.44M |
| Financing cash flow | $8.71M | $27.01M |
| Depreciation & amortization | $5.72M | $5.97M |
| Stock-based compensation | $54.51M | $49.13M |
Free plan shows the latest 2 periods; Pro shows all 10 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.